相关实验视频

Updated: May 22, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

后COVID-19炎症性关节炎治疗与upadacitinib:一个案例报告

Cherie S Zhi¹, Ami Ben-Artzi¹

¹Rheumatology, Ami Ben-Artzi, MD Inc., Scripps Hospital, San Diego, USA.

|March 13, 2025

概括

两名患者在COVID-19后患有炎症性关节炎. 使用Janus激酶抑制剂upadacitinib的治疗显示出积极的结果,表明其在管理COVID-19后关节炎症方面的潜力.

科学领域:

类风湿病学类风湿病学
传染性疾病传染性疾病
药理学药理学是指药理学的学科.

背景情况:

COVID-19 感染可以引发各种自身免疫和炎症性疾病.
后病毒性炎症性关节炎是SARS-CoV-2感染后出现的并发症.
简氏激酶抑制剂 (JAKi) 是一种针对性免疫调节疗法的类别.

研究的目的:

报告两例COVID-19后发展的炎症性关节炎病例.
为了评估upadacitinib在治疗COVID-19后炎症性关节炎中的疗效和安全性.
为了突出这一特定患者群体的潜在治疗选择.

主要方法:

两名患有COVID-19后炎症性关节炎的患者的病例报告介绍.
临床评估包括关节炎,关节炎和炎症的实验室标志物 (例如,C反应蛋白).
使用选择性的Janus激酶抑制剂upadacitinib进行治疗.

主要成果:

这两位患者在COVID-19后呈现炎症性关节炎症状.
观察到炎症标志物增加,例如C-反应蛋白.
这两位患者在接受上达西提尼布治疗后均表现出临床显著的改善.

结论:

在COVID-19之后,upadacitinib可能是炎症性关节炎的有效治疗方法.
在这些情况下,Janus 激酶抑制剂表现出了有利的安全性.
这份病例报告表明,upadacitinib 是一种可行的治疗策略,用于管理COVID-19后炎症性关节炎症.

关键词:

自免疫分子仿真自免疫分子仿真炎症性关节炎是一种炎症性关节炎.雅克抑制剂雅克抑制剂在Covid-19中分子模拟.多关节痛症多关节痛症多关节性关节炎多关节性关节炎在COVID-19后的综合症.在COVID-19后的情形中.在此之前,upadacitinib 已经在使用中.病毒性关节炎病毒性关节炎

更多相关视频

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...